ASRGL1: A potential therapeutic target in the treatment of hepatocellular carcinoma?

Dig Liver Dis. 2023 Sep;55(9):1306. doi: 10.1016/j.dld.2023.03.014. Epub 2023 Apr 14.

Authors

Jing Zhang¹, Yan-Li Hou², Xiao-Cong Liu³, Hao Dong⁴

Affiliations

¹ Department of Oncology, Zibo Central Hospital, Zibo 255000, China.
² Department of Supervision Office of Nursing, Zibo Central Hospital, Zibo 255000, China.
³ Department of Clinical Laboratory, Zibo Central Hospital, Zibo 255000, China.
⁴ Department of orthopedics, Zibo Central Hospital, Zibo 255000, China. Electronic address: 18560290778@163.com.

PMID: 37062626
DOI: 10.1016/j.dld.2023.03.014

No abstract available

Publication types

Letter
Comment

MeSH terms

Biomarkers, Tumor
Carcinoma, Hepatocellular* / drug therapy
Carcinoma, Hepatocellular* / pathology
Cell Line, Tumor
Humans
Liver Neoplasms* / drug therapy
Liver Neoplasms* / pathology

Substances

Biomarkers, Tumor